New research describes how sphingolipids can also contribute to arterial plaques and atherosclerosis, revealing a new side to ...

Aug. 14, 2024 — More than a quarter of Australians over the age of 50 take cholesterol-lowering drugs to prevent heart ... Researchers have identified a mechanism that can improve current ...

Altered sphingolipid biosynthetic flux and lipoprotein trafficking contribute to trans fat-induced atherosclerosis - (https:/ ...

Common cardiovascular drugs are linked to a lower risk of dementia in older age, according to a new study from Karolinska ...

Most people don't enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such ...

In China, the revenue in the Lipid-Lowering Agents market is forecasted to reach US$860.90m by 2024. It is anticipated that the revenue will exhibit a compound annual growth rate (CAGR 2024-2029 ...

A groundbreaking study from Karolinska Institutet suggests that long-term use of certain cardiovascular medications can ...

Zerlasiran was found to be well tolerated and no significant safety concerns were observed. Credit: Good dreams - Studio via ...